Immunotherapy for severe aplastic anemia following orthotopic liver transplantation in children.
Severe aplastic anemia is a well-recognized complication of fulminant non-A, non-B, and non-C hepatitis requiring orthotopic liver transplantation. The first line of therapy for cure in the treatment of aplastic anemia is a histocompatible bone marrow transplant. Immunosuppressive therapy is also effective if a histocompatible donor is not available. We describe two children who developed severe aplastic anemia following orthotopic liver transplant who achieved bone marrow recovery with a single course of anti-thymocyte globulin, solumedrol, and adjustments to their immunosuppressive therapy for prevention of liver allograft rejection.
Sanchez
Rosa
R
Department of Pediatrics, University of California, San Francisco, California 94143-0106, USA. rsanchez@itsa.ucsf.edu
Rosenthal
Philip
P
Goldsby
Robert
R
D000741:Anemia, Aplastic / Q000209:etiology / Q000628:therapy*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D005260:Female; D006505:Hepatitis / Q000601:surgery*; D006801:Humans; D007167:Immunotherapy; D016031:Liver Transplantation / Q000009:adverse effects*; D008297:Male; D008776:Methylprednisolone Hemisuccinate / Q000627:therapeutic use*; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D008776:Methylprednisolone Hemisuccinate